```
=> d his

     (FILE 'HOME' ENTERED AT 12:56:02 ON 12 MAY 2005)

     FILE 'CAPLUS' ENTERED AT 12:56:10 ON 12 MAY 2005
L1         27343 S CYCLODEXTRIN
L2          2128 S L1 AND POLYMER
L3           685 S L2 AND INCLUSION
L4           246 S L3 AND "INCLUSION COMPLEX"
L5             4 S L4 AND "COMPLEXING AGENT"

=> d bib abs 1-5

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:857318  CAPLUS
DN   141:337741
TI   A stable ophthalmic composition containing steroids and cyclodextrins
IN   Laddha, Nitin Ritu; Bhowmick, Balaram Subhas
PA   Sun Pharmaceutical Industries Limited, India
SO   PCT Int. Appl., 15 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2004087043         A2    20041014    WO 2004-IN48             20040223
     WO 2004087043         A3    20041216
     WO 2004087043         B1    20050127
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI IN 2003-MU212         A     20030221
AB   The present invention provides a clear stable ophthalmic composition comprising
     (a) an anti-infective agent; (b) a steroidal anti-inflammatory agent; (c)
     a complexing agent capable of forming an
     inclusion complex and (d) other pharmaceutically
     acceptable excipients in a liquid vehicle such that the composition is free of
     any other complexation enhancing polymer and such composition when
     stored at room temperature for one year does not show any precipitation over
the storage
     period.  A composition contained ciprofloxacin-HCl, dexamethasone, mannitol,
     hydroxypropyl β- cyclodextrin, di-Na edetate, benzalkonium
     chloride solution, and water for injection.

L5   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2002:487421  CAPLUS
DN   137:47645
TI   Preparation of adamantyl-polyethylene glycol containing sugar and peptide
     residues and inclusion complexes as therapeutic agents
IN   Hwang, Pun Suzie; Gonzalez, Hector; Davis, Mark E.; Bellocq, Nathalie;
     Cheng, Jianjun
PA   California Institute of Technology, USA; Insert Therapeutics, Inc.
SO   PCT Int. Appl., 138 pp.
     CODEN: PIXXD2
```

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049676	A2	20020627	WO 2001-US48620	20011219
	WO 2002049676	A3	20021227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431207	AA	20020627	CA 2001-2431207	20011219
	AU 2002029065	A5	20020701	AU 2002-29065	20011219
	US 2003008818	A1	20030109	US 2001-21312	20011219
	US 2003017972	A1	20030123	US 2001-21294	20011219
	EP 1351710	A2	20031015	EP 2001-990201	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001016346	A	20040706	BR 2001-16346	20011219
	JP 2004523502	T2	20040805	JP 2002-551013	20011219
	ZA 2003004562	A	20040803	ZA 2003-4562	20030611
PRAI	US 2000-256341P	P	20001219		
	US 2000-256344P	P	20001219		
	US 2001-293543P	P	20010529		
	WO 2001-US48620	W	20011219		

AB The invention provides a composition containing particulate composite of a **polymer** with a formula of adamantyl-(CH2)n-Ja-PEGx-Lb-(functional group)y wherein J is NH, C(O)NH(CH2)d, NHC(O)(CH2)d, XH2SS, CO2,(CH2)eOP(O)[O(CH2)e-adamantyl]O, peptide, polypeptide, NH(CO)CHR1NH(CO)CHR1NH; R1 is (CH2)aCO2H, (CH2)aCONH2; PEG is O(CH2CH2O)z; where z is 2-500; L is H, NH2, NH(CO)(CH2)e(CO)CH2, SO2CH:CH2, SS, CO2, carbohydrate residue; a is 0-1, b is 0-1; d is 0-6; e is 1-6; yr is 0-1, x is 0-1, and a therapeutic agent. The composition also contains a **complexing agent**. The **polymer** interacts with the **complexing agent** in a host-guest or a guest-host interaction to form an **inclusion complex**. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the **polymer** of the particulate composite and the **complexing agent** may be used to introduce functionality into the therapeutic composition The invention also relates to a method of preparing a composition The method combines a therapeutic agent, a **polymer** having host or guest functionality, and a **complexing agent** having guest or host functionality to form the therapeutic composition The **complexing agent** forms an **inclusion complex** with the **polymer**. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. human or animal) in recognized need of the therapeutic.

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:573841 CAPLUS
DN 133:178030
TI Polymers of **cyclodextrin** and/or **cyclodextrin** derivatives with complexing properties and ion-exchange properties and method for the production thereof
IN Weltrowski, Marek; Morcellet, Michel; Martel, Bernard

PA Universite des Sciences et Technologies de Lille, Fr.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047630	A1	20000817	WO 2000-FR377	20000215
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2789685	A1	20000818	FR 1999-1968	19990215
	FR 2789685	B1	20010504		
	EP 1165621	A1	20020102	EP 2000-905143	20000215
	EP 1165621	B1	20021002		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 225372	E	20021015	AT 2000-905143	20000515
	US 6660804	B1	20031209	US 2001-913475	20010815
PRAI	FR 1999-1968	A	19990215		
	WO 2000-FR377	W	20000215		

AB The invention relates to a method for the production of polymers of **cyclodextrin** and/or **cyclodextrin** derivs., characterized by the following operations: preparation in a solid state of a mixture of **cyclodextrin** and/or **cyclodextrin** derivative(s) and/or **inclusion complex**(es) of **cyclodextrin** and/or **cyclodextrin** derivs. and/or a polycarboxylic acid anhydride or a mixture of polycarboxylic acids and/or polycarboxylic acid anhydrides and optionally a catalyst; heating of said solid mixture to a temperature of between 100-200° during a period of 1-60 min, preferably a period that is substantially the same as or equal to 30 min. A typical **polymer** was manufactured by evaporating 25 mL solution containing β- **cyclodextrin** 100, citric acid 100, and Na hydrogen phosphate 30 g/L under vacuum at 90° and heating the residue 30 min at 170°.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:613711 CAPLUS
DN 131:248243
TI Oral pharmaceutical compositions to be taken without liquids, which contain **inclusion** complexes
IN Santus, Giancarlo; Golzi, Roberto; Lazzarini, Caterina; Marcelloni, Luciano
PA Recordati S.A. Chemical and Pharmaceutical Company, Switz.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947172	A2	19990923	WO 1999-EP1540	19990310
	WO 9947172	A3	19991111		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	IT 1298732	B1	20000202	IT 1998-MI511	19980313
	AU 9929326	A1	19991011	AU 1999-29326	19990310
PRAI	IT 1998-MI511	A	19980313		
	WO 1999-EP1540	W	19990310		

AB Pharmaceutical compns. for oral administration are provided which contain **inclusion** complexes and are characterized by rapid release of the active ingredient. These compns. require no use of liqs. for administration; the saliva present in the oral cavity is adequate for dissoln. of the active ingredient. The formulations are particularly useful for increasing the bioavailability of active ingredients which are insol. or slightly soluble in water, especially in cases requiring a rapid therapeutic response, and for increasing patient compliance. The **complexing agent** is a water-soluble agent such as **cyclodextrin**, a hydrophilic linear **polymer** such as PVP or a cellulose derivative, or a crosslinked **polymer** which swells on contact with water. The compns. may take the form of rapidly disintegrating tablets, chewable tablets, effervescent tablets, chewing gum, or lyophilized tablets. Thus, a solution of 12 g nimesulide in 80 mL 0.5M NaOH was mixed with a suspension of 97 g β- **cyclodextrin** in 1200 mL distilled water, the pH was adjusted to 8.5, and the mixture was lyophilized. The resulting complex 800 was mixed with xylitol 390, crosslinked PVP 80, AcDiSol 800, Mg stearate 10, Glycamil (licorice flavoring) 20, lemon flavoring 10, and aspartame 10 g in a V mixer and pressed into 1400-mg tablets.

=>